Administer's Q2 was slightly weaker than expected, with the y/y EBITDA improvement streak coming to a pause. Adjustment measures have been initiated to support margins going forward. The Sarastia acquisition, which will increase revenues by close to 50%, continues to represent a potential catalyst for 2026 and beyond.
LÄS MER
